IDH1 and acute myeloid leukemia: A phase 1, Multicenter, Open-label, Safety study of AG-120 or AG-221 in combination with induction therapy and consolidation therapy in patients with newly diagnosed acute myeloid leukemia with an IDH1 and/or IDH2 mutation